Findings

What do systematic reviews say?

1,494 questions · 1,521 findings · 132 reviews · Hepato-Biliary

Sort:Best matchNewestHighest certainty Download CSV

No studies found 303 · 19.9%GRADE not reported 39 · 2.6%Very low 876 · 57.6%Low 216 · 14.2%Moderate 65 · 4.3%High 22 · 1.4%

Miniport laparoscopic cholecystectomy vs standard port laparoscopic cholecystectomy

Return to activity · patients with laparoscopic cholecystectomy.

1 finding from 1 review

Miniports versus standard ports for laparoscopic cholecystectomy 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 52 participants
Low

Miniport laparoscopic cholecystectomy vs standard port laparoscopic cholecystectomy

Return to work · patients with laparoscopic cholecystectomy.

1 finding from 1 review

Miniports versus standard ports for laparoscopic cholecystectomy 2013 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 187 participants
Low

Miniport laparoscopic cholecystectomy vs standard port laparoscopic cholecystectomy

Cosmesis · patients with laparoscopic cholecystectomy.

1 finding from 1 review

Miniports versus standard ports for laparoscopic cholecystectomy 2013 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 152 participants
Very low

Intervention vs control

All‐cause mortality · high‐risk surgical patients with acute calculous cholecystitis.

It is very uncertain whether intervention changes mortality compared with control (very low certainty).

1 finding from 1 review

Percutaneous cholecystostomy for high‐risk surgical patients with acute calculous cholecystitis 2013 · Cochrane Headline outcomes only
RR 0.3 [0.01, 7.08]
1 study · 70 participants
Very low

Intervention vs control

Serious adverse events · high‐risk surgical patients with acute calculous cholecystitis.

It is very uncertain whether intervention changes serious adverse events compared with control (very low certainty).

1 finding from 1 review

Percutaneous cholecystostomy for high‐risk surgical patients with acute calculous cholecystitis 2013 · Cochrane Headline outcomes only
RR 0.45 [0.04, 4.7]
1 study · 70 participants
Very low

Early vs delayed laparoscopic cholecystectomy

All‐cause mortality · people with biliary colic

It is very uncertain whether early changes mortality compared with delayed laparoscopic cholecystectomy (very low certainty).

1 finding from 1 review

Early versus delayed laparoscopic cholecystectomy for uncomplicated biliary colic 2013 · Cochrane Headline outcomes only
RR 0.38 [0.02, 9.03]
1 study · 75 participants
Very low

Early vs delayed laparoscopic cholecystectomy

Serious adverse events · people with biliary colic

It is very uncertain whether early changes serious adverse events compared with delayed laparoscopic cholecystectomy (very low certainty).

1 finding from 1 review

Early versus delayed laparoscopic cholecystectomy for uncomplicated biliary colic 2013 · Cochrane Headline outcomes only
RR 0.07 [0, 1.23]
1 study · 68 participants
Very low

Early vs delayed laparoscopic cholecystectomy

Conversion to open cholecystectomy · people with biliary colic

It is very uncertain whether early changes conversion to open cholecystectomy compared with delayed laparoscopic cholecystectomy (very low certainty).

1 finding from 1 review

Early versus delayed laparoscopic cholecystectomy for uncomplicated biliary colic 2013 · Cochrane Headline outcomes only
RR 0.1 [0.01, 1.63]
1 study · 63 participants
Very low

Early vs delayed laparoscopic cholecystectomy

Length of hospital stay · people with biliary colic

1 finding from 1 review

Early versus delayed laparoscopic cholecystectomy for uncomplicated biliary colic 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 63 participants
Very low

Early vs delayed laparoscopic cholecystectomy

Operating time · people with biliary colic

1 finding from 1 review

Early versus delayed laparoscopic cholecystectomy for uncomplicated biliary colic 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 63 participants
Very low

Ursodeoxycholic acid vs placebo or no intervention

All‐cause mortality · patients with primary biliary cirrhosis.

It is very uncertain whether ursodeoxycholic acid changes all‐cause mortality compared with placebo or no intervention (very low certainty).

1 finding from 1 review

Ursodeoxycholic acid for primary biliary cirrhosis 2012 · Cochrane Headline outcomes only
RR 0.97 [0.67, 1.42]
14 studies · 1391 participants
Very low

Ursodeoxycholic acid vs placebo or no intervention

All‐cause mortality or liver transplantation · patients with primary biliary cirrhosis.

It is very uncertain whether ursodeoxycholic acid changes all‐cause mortality or liver transplantation compared with placebo or no intervention (very low certainty).

1 finding from 1 review

Ursodeoxycholic acid for primary biliary cirrhosis 2012 · Cochrane Headline outcomes only
RR 0.96 [0.74, 1.25]
15 studies · 1419 participants
Very low

Ursodeoxycholic acid vs placebo or no intervention

Serious adverse events · patients with primary biliary cirrhosis.

It is very uncertain whether ursodeoxycholic acid changes serious adverse events compared with placebo or no intervention (very low certainty).

1 finding from 1 review

Ursodeoxycholic acid for primary biliary cirrhosis 2012 · Cochrane Headline outcomes only
RR 0.87 [0.68, 1.12]
14 studies · 1382 participants
Very low

Ursodeoxycholic acid vs placebo or no intervention

Non‐serious adverse events · patients with primary biliary cirrhosis.

It is very uncertain whether ursodeoxycholic acid changes non‐serious adverse events compared with placebo or no intervention (very low certainty).

1 finding from 1 review

Ursodeoxycholic acid for primary biliary cirrhosis 2012 · Cochrane Headline outcomes only
RR 1.46 [0.83, 2.56]
12 studies · 1277 participants
Very low

Ursodeoxycholic acid vs placebo or no intervention

Pruritus · patients with primary biliary cirrhosis.

Ursodeoxycholic acid showed no clear difference in pruritus compared with placebo or no intervention (low certainty).

1 finding from 1 review

Ursodeoxycholic acid for primary biliary cirrhosis 2012 · Cochrane Headline outcomes only
RR 0.96 [0.84, 1.09]
6 studies · 630 participants
Low

Ursodeoxycholic acid vs placebo or no intervention

Bilirubin (µmol/L) · patients with primary biliary cirrhosis.

1 finding from 1 review

Ursodeoxycholic acid for primary biliary cirrhosis 2012 · Cochrane Headline outcomes only
no estimate extracted
9 studies · 881 participants
Low

Ursodeoxycholic acid vs placebo or no intervention

Liver biopsy findings (worsening of histological stage) · patients with primary biliary cirrhosis.

It is very uncertain whether ursodeoxycholic acid changes liver biopsy findings (worsening of histological stage) compared with placebo or no intervention (very low certainty).

1 finding from 1 review

Ursodeoxycholic acid for primary biliary cirrhosis 2012 · Cochrane Headline outcomes only
RR 0.62 [0.44, 0.88]
7 studies · 551 participants
Very low

Summary of findings table ‐ Recombinant activated factor VII vs placebo

Mortality within 5 days · patients with upper gastrointestinal bleeding and liver diseases.

Recombinant human factor VII activated showed no clear difference in mortality within 5 days compared with placebo (moderate certainty).

1 finding from 1 review

Human recombinant activated factor VII for upper gastrointestinal bleeding in patients with liver diseases 2012 · Cochrane Headline outcomes only
RR 0.95 [0.36, 2.5]
2 studies · 493 participants
Moderate

Summary of findings table ‐ Recombinant activated factor VII vs placebo

Mortality within 42 days · patients with upper gastrointestinal bleeding and liver diseases.

Recombinant human factor VII activated showed no clear difference in mortality within 42 days compared with placebo (moderate certainty).

1 finding from 1 review

Human recombinant activated factor VII for upper gastrointestinal bleeding in patients with liver diseases 2012 · Cochrane Headline outcomes only
RR 1.01 [0.55, 1.87]
2 studies · 491 participants
Moderate

Summary of findings table ‐ Recombinant activated factor VII vs placebo

Adverse events (overall incidence) · patients with upper gastrointestinal bleeding and liver diseases.

Recombinant human factor VII activated showed no clear difference in adverse events (overall incidence) compared with placebo (high certainty).

1 finding from 1 review

Human recombinant activated factor VII for upper gastrointestinal bleeding in patients with liver diseases 2012 · Cochrane Headline outcomes only
RR 0.94 [0.84, 1.04]
2 studies · 507 participants
High